Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$35.20M$35.20M+4.3% vs Q2 2017 Net Income-$22.89M-$22.89MN/M vs Q2 2017 EPS Diluted-$0.16-$0.16N/M vs Q2 2017 Gross Profit$3,647,000−26.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$18,858,000N/M Free Cash Flowderived-$19,276,000N/M Margins · derivedGross margin10.4%−4.4 pt vs Q2 2017
Operating margin-57.0%+18.5 pt vs Q2 2017
Net margin-65.0%+26.1 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 7, 2018 · 38 d after period end